“…Table 1 summarizes the results of functional neuroimaging studies with Single Photon Emission Computerized Tomography (SPECT) or Positron Emission Tomography (PET) reported to date in patients diagnosed with RBD, including those using different methods and tracers for the presynaptic dopaminergic (DA) terminal and postsynaptic dopamine D 2 receptors (DRD 2 ). The majority of studies analyzing the presynaptic DA terminal have shown a significant decrease in the striatal tracer uptake in many patients diagnosed, at least initially, with iRBD [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 ], with some exceptions [ 45 ], being this decrease lower than that found in patients diagnosed with PD [ 27 , 28 , 31 , 43 , 45 ] or LBD [ 43 ] with or without concomitant RBD, although PD patients with versus those without RBD did not show significant differences [ 46 ]. However, patients with and without decreased striatal tracer uptake did not differ in clinical features according to one study [ 32 ], while in others, iRBD patients with mild motor impairment or with higher Unified Parkinsonâs Disease Rating Scale (UPDRS) motor score showed decreased striatal tracer uptake when compared with those without mild motor impairment and with controls [ 33 , 34 ].…”